Track topics on Twitter Track topics that are important to you
ZUG, Switzerland, June 2, 2015 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (Nasdaq:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that Thomas Meyer, Ph.D., Chairman and CEO, will present at the Jefferies 2015 Global Healthcare Conference on Tuesday, June 2, 2015, at 11:00 a.m. EDT, at the Grand Hyatt Hotel in New York. A live webcast of the presentation will be available through the Events and Presentations page in the Investors section of the Company's website (www.aurismedical.com).
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland.
Auris Medical Jefferies Global Healthcare Conference Announcement http://hugin.info/160190/R/1925632/690939.pdf
CONTACT: Dr. Thomas Meyer, Chairman and CEO, +41 41 729 71 94, email@example.com Investors: Matthew P. Duffy, Managing Director, LifeSci Advisors, 212-915-0685, firstname.lastname@example.orgNEXT ARTICLE
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...